Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and is expected to improve Myriad's revenue growth, profitability, and balance sheet. Despite the upgrade, the price target implies a potential 13.2% downside from the current share price of $5.76. The transaction marks a strategic shift for Myriad Genetics as it focuses on strengthening its financial position.
Myriad Genetics' recent stock upgrade and sale deal provide context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 02:12 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 133 rose and 16 fell today. Notable movers include AMWL at USD 13.18 with a 1-day change of +6.89% and a typical hold time of 62 days, MRNA at USD 242.34 with a 1-day change of +6.81% and Pluang order activity showing 40% Sell and 60% Buy, and AMLX at USD 29.17 with a 1-day change of +6.73% and a typical hold time of 16 days.
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Brunello Cucinelli, an Italian luxury fashion company, raised its 2026 outlook following stronger-than-expected third-quarter sales. Citigroup maintains a Buy rating on the stock, which trades around $9.43 with a market cap of approximately $6.41 bil...
H.C. Wainwright upgraded Rapport Therapeutics' price target from $40 to $66 following positive Phase 2 trial results of RAP-219 for acute bipolar mania. The drug met its primary endpoint, showing significant symptom improvement, and is moving toward ...
MSCI reported better-than-expected results for Q3 2026, with adjusted earnings per share of $5.11 and revenue of $892 million, surpassing estimates. Revenue grew 12.4% year-over-year, driven by recurring subscriptions and asset-based fees, which rose...
Capital One Financial is set to report its Q3 2026 earnings on October 20, with analysts forecasting revenue growth driven by strong credit card activity, including a 23.3% rise in interchange fees and a 2.5% increase in net interest income. However,...
